ATE546430T1 - Fkbp bindende zusammensetzung und deren pharmazeutische verwendung - Google Patents
Fkbp bindende zusammensetzung und deren pharmazeutische verwendungInfo
- Publication number
- ATE546430T1 ATE546430T1 AT05763770T AT05763770T ATE546430T1 AT E546430 T1 ATE546430 T1 AT E546430T1 AT 05763770 T AT05763770 T AT 05763770T AT 05763770 T AT05763770 T AT 05763770T AT E546430 T1 ATE546430 T1 AT E546430T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- pharmaceutical use
- binding composition
- fkbp binding
- composition
- Prior art date
Links
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 title abstract 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58374004P | 2004-06-29 | 2004-06-29 | |
| US62494604P | 2004-11-04 | 2004-11-04 | |
| PCT/US2005/022360 WO2006012256A2 (en) | 2004-06-29 | 2005-06-24 | Fkbp binding composition and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE546430T1 true ATE546430T1 (de) | 2012-03-15 |
Family
ID=35502420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05763770T ATE546430T1 (de) | 2004-06-29 | 2005-06-24 | Fkbp bindende zusammensetzung und deren pharmazeutische verwendung |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1778637B1 (de) |
| JP (1) | JP4812758B2 (de) |
| AT (1) | ATE546430T1 (de) |
| DK (1) | DK1778637T3 (de) |
| ES (1) | ES2383123T3 (de) |
| PT (1) | PT1778637E (de) |
| WO (1) | WO2006012256A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| EP4159737A4 (de) * | 2020-05-28 | 2024-10-09 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Verfahren zur herstellung einer glp-1-rezeptoragonistfreien base |
| WO2023178378A1 (en) * | 2022-03-21 | 2023-09-28 | DMTC Limited | Mip inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798355A (en) * | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| US7056935B2 (en) * | 1995-06-07 | 2006-06-06 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| EP1001764A4 (de) * | 1997-05-29 | 2005-08-24 | Merck & Co Inc | Heterozyklische amide als zelladhäsionshemmern |
| WO1999006436A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
| US6268384B1 (en) * | 1997-08-29 | 2001-07-31 | Vertex Pharmaceuticals Incorporated | Compounds possessing neuronal activity |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
| US6218423B1 (en) * | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
| AT500282A3 (de) * | 2002-03-28 | 2006-06-15 | Jsw Res Forschungslabor Gmbh | Neurotrophe und neuroprotektive peptide |
-
2005
- 2005-06-24 PT PT05763770T patent/PT1778637E/pt unknown
- 2005-06-24 DK DK05763770.4T patent/DK1778637T3/da active
- 2005-06-24 JP JP2007519296A patent/JP4812758B2/ja not_active Expired - Fee Related
- 2005-06-24 AT AT05763770T patent/ATE546430T1/de active
- 2005-06-24 EP EP05763770A patent/EP1778637B1/de not_active Expired - Lifetime
- 2005-06-24 WO PCT/US2005/022360 patent/WO2006012256A2/en not_active Ceased
- 2005-06-24 ES ES05763770T patent/ES2383123T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006012256A2 (en) | 2006-02-02 |
| EP1778637B1 (de) | 2012-02-22 |
| DK1778637T3 (da) | 2012-06-18 |
| EP1778637A2 (de) | 2007-05-02 |
| JP2008505077A (ja) | 2008-02-21 |
| ES2383123T3 (es) | 2012-06-18 |
| WO2006012256A3 (en) | 2006-04-27 |
| JP4812758B2 (ja) | 2011-11-09 |
| PT1778637E (pt) | 2012-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60322713D1 (de) | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung | |
| CY1109722T1 (el) | Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole | |
| BRPI0307351B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto | |
| BRPI0518459A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| BRPI0508390A (pt) | métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| CY1112960T1 (el) | Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων | |
| WO2008039829A3 (en) | Diphenylheterocycle cholesterol absorption inhibitors | |
| DE502006006107D1 (de) | Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| DE502004002117D1 (de) | Substituierte thiazol-benzoisothiazoldioxidderivative, verfahren zu deren herstellung und deren verwendung | |
| TW200500339A (en) | Pyrrolidine derivatives, and process for the preparation | |
| ATE472541T1 (de) | N-(1-alkyl-2-phenylethyl)carbonsäureamidderivat und deren verwendung als fungizide | |
| DE602005010821D1 (de) | Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren | |
| ATE538119T1 (de) | Benzothiazolcyclobutylamin-derivate und deren verwendung als histamin-3-rezeptor-liganden | |
| DK1363876T3 (da) | Glucocorticoidreceptormodulatorer | |
| BRPI0615158A8 (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto. | |
| ATE543803T1 (de) | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren | |
| ATE546430T1 (de) | Fkbp bindende zusammensetzung und deren pharmazeutische verwendung | |
| ATE439831T1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
| WO2005072408A3 (en) | Treating a viral disorder | |
| DE60204611D1 (de) | Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren | |
| ATE525382T1 (de) | Azazucker-derivate, heparanase-hemmer, verfahren zu deren herstellung, zusammensetzungen damit und verwendung | |
| ATE448223T1 (de) | 8-azabicycloä3.2.1üoctanderivate und ihre verwendung als monoamine-neurotransmitter- reuptake inhibitoren | |
| ATE488510T1 (de) | Heterocyclische derivate, deren herstellung und therapeutische verwendung | |
| EP1483233A4 (de) | Substituierte tetrahydro isochinolinverbindungen, verfahren zu deren herstellung und deren verwendung |